Shire

Company snapshot

Shire is now part of Takeda. Follow us at https://www.linkedin.com/company/takeda-pharmaceuticals/

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shire. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Shire.

1. Jun 8, 2026 Clinical update

   Recombinant human arylsulfatase A — Phase 2

2. Jun 8, 2026 Clinical update

   Elaprase for intravenous (IV) infusion — Approved

3. Jun 5, 2026 Clinical update

   SHP611 — Phase 2

4. Jun 5, 2026 Clinical update

   rhASA — Phase 2

5. Jun 5, 2026 Clinical update

   rhASA — Phase 2

View all clinical trial activity →

• What is Shire?

  Shire is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome, Cytomegalovirus (CMV), Crohn's Disease. NovaPharmaNews links 9 clinical program(s), 0 drug pro

• Is Shire publicly traded?

  Shire appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shire develop or market?

  We link 8 drug profile(s) where Shire is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shire-pharmaceutical-contracts-limited#company-drugs.

• What are the latest developments for Shire?

  In the last 12 months our linked public records show 9 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Shire focus on?

  Shire focuses on Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome based on our analysis of their pipeline programs and drug development activities.